Cargando…

Corrigendum to: Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population

Detalles Bibliográficos
Autores principales:	Spring, Michele D, Sousa, Jason C, Li, Qigui, Darko, Christian A, Morrison, Meshell N, Marcsisin, Sean R, Mills, Kristin T, Potter, Brittney M, Paolino, Kristopher M, Twomey, Patrick S, Moon, James E, Tosh, Donna M, Cicatelli, Susan B, Froude, Jeffrey W, Pybus, Brandon S, Oliver, Thomas G, Mccarthy, William F, Waters, Norman C, Smith, Philip L, Reichard, Gregory A, Bennett, Jason W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Corrigenda
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075415/ https://www.ncbi.nlm.nih.gov/pubmed/31773155 http://dx.doi.org/10.1093/infdis/jiz599

Ejemplares similares

Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population
por: Spring, Michele D, et al.
Publicado: (2019)

The metabolism of primaquine to its active metabolite is dependent on CYP 2D6
por: Pybus, Brandon S, et al.
Publicado: (2013)

Pre-clinical evaluation of CYP 2D6 dependent drug–drug interactions between primaquine and SSRI/SNRI antidepressants
por: Jin, Xiannu, et al.
Publicado: (2016)

Enantioselective metabolism of primaquine by human CYP2D6
por: Fasinu, Pius S, et al.
Publicado: (2014)

Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei
por: Milner, Erin E., et al.
Publicado: (2016)

Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes
por: Fasinu, Pius S., et al.
Publicado: (2016)

Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax
por: Stewart, Alexandra G. A., et al.
Publicado: (2021)

A Review of the Important Role of CYP2D6 in Pharmacogenomics
por: Taylor, Christopher, et al.
Publicado: (2020)

Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections
por: Li, Qigui, et al.
Publicado: (2014)

Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children
por: Gonçalves, Bronner P., et al.
Publicado: (2017)

CYP2D6 Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for Plasmodium falciparum
por: Pett, Helmi, et al.
Publicado: (2019)

Global perspectives on CYP2D6 associations with primaquine metabolism and Plasmodium vivax radical cure
por: Olvany, Jasmine M., et al.
Publicado: (2022)

CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine
por: Pybus, Brandon S, et al.
Publicado: (2012)

Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry
por: Jarvis, Joseph P., et al.
Publicado: (2019)

Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds
por: Marcsisin, Sean R, et al.
Publicado: (2014)

Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes
por: Fasinu, Pius S., et al.
Publicado: (2019)

Modelling primaquine-induced haemolysis in G6PD deficiency
por: Watson, James, et al.
Publicado: (2017)

Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS/MS: Its Application to a Pharmacokinetic Study
por: Pookmanee, Waritda, et al.
Publicado: (2021)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
por: Stojiljkovic, Maja, et al.
Publicado: (2012)

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
por: Baird, J. Kevin, et al.
Publicado: (2018)

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
por: Chu, Cindy S., et al.
Publicado: (2018)

Barriers to routine G6PD testing prior to treatment with primaquine
por: Ley, Benedikt, et al.
Publicado: (2017)

G6PD Variants and Haemolytic Sensitivity to Primaquine and Other Drugs
por: Bancone, Germana, et al.
Publicado: (2021)

Isoenzymes of hexokinase, 6-phosphogluconate dehydrogenase, phosphoglucomutase and lactate dehydrogenase in uterine cancer.
por: Marshall, M. J., et al.
Publicado: (1979)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
por: Sychev, Dmitry Alekseevich, et al.
Publicado: (2016)

Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants
por: Cacabelos, Ramón, et al.
Publicado: (2010)

Association of CYP2C19, CYP2D6 and CYP3A4 Genetic Variants on Primaquine Hemolysis in G6PD-Deficient Patients
por: Macêdo, Marielle M., et al.
Publicado: (2023)

An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria infection model
por: Livezey, Jeffrey, et al.
Publicado: (2020)

CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine
por: Pett, Helmi, et al.
Publicado: (2014)

Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function
por: Martin Ramírez, Alexandra, et al.
Publicado: (2020)

Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases
por: de Pina-Costa, Anielle, et al.
Publicado: (2021)

Isoenzymes in Biology and Medicine
por: Holmes, Roger S.
Publicado: (1969)

Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
por: Reis, Sara S., et al.
Publicado: (2019)

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients
por: Avalos, Sara, et al.
Publicado: (2018)

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria
por: Baird, J. Kevin, et al.
Publicado: (2018)

Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function
por: Choi, Sungim, et al.
Publicado: (2022)

Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites
por: Li, Qigui, et al.
Publicado: (2017)

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination
por: Howes, Rosalind
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0rpbarg6vq0lf6doi2p3nijom8